2021 Global Drug Bioavailability Enhancement Summit (San Diego, CA, United States – January 25-27, 2021) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2021 Global Drug Bioavailability Enhancement Summit” conference has been added to ResearchAndMarkets.com’s offering.

Gather insights into the latest technologies and methods of new drug formulation and bioavailability enhancement strategies.

It’s no lie the drug development model is in need of a drastic shakeup. With lengthy and costly approval processes, generic incursion, rising development costs and the need for novel adherence strategies, pharma and biotech, now more than ever need to initiate innovative formulation, delivery and development approaches in order to improve bioavailability and therapeutic performance.

We’re here to help. The 2021 Global Drug Bioavailability Enhancement Summit will connect industry leaders from both small molecule and biologics areas to address challenges at the interface between drug discovery and preclinical/clinical development. 2021’s Summit will share cutting edge research on the development, characterization and manufacture of formulations that span multiple modalities. Hear from 30+ senior drug bioavailability pioneers and network with 120+ senior drug development innovators and walk away with over 2 years of new drug formulation and bioavailability enhancement approaches strategies in just 2 days!

Are you looking to improve drug performance, bioavailability and patient adherence? Would you like to reduce dosage, cost and time-to-market? Get involved today at the 2021 Summit and dramatically increase the performance and activity of your current and future drug products.

• 30+ Industry-led Speakers
• 120+ Senior Participants
• 14+ Networking Hours
• 16 Tech Exhibitors

You Will Learn

• Precision medicine & healthcare delivery
• Rationale formulation design for poorly soluble compounds
• In-vivo – in-vitro correlation
• Solution behavior of amorphous solid dispersions
• Nanosuspension for improving the bioavailability
• Early formulation screening in drug discovery
• 3D printing for biopharmaceuticals
• Enhancing patient adherence via drug delivery
• Innovative strategies around drug/device combinations

Speakers

Rakesh Dixit, PhD

President & CEO

Bionavigen

Ildiko Terebesi, PhD

Head, Early Formulation Development

Bayer

Wei Zhu, PhD

Senior Scientist, Biopharmaceutics & Speciality Dosage Forms

Merck & Co.

Rick Panicucci, PhD

Senior Vice President, CMC

QED Therapeutics

Dedong Wu, PhD

Senior Scientist, Pharmaceutical Science

AstraZeneca

Doug Nesta, PhD

Senior Director, Biopharmaceutical Product Sciences

GlaxoSmithKline

Dina Zhang, PhD

Senior Research Fellow

Merck & Co.

John Morrison, PhD

Senior Research Investigator

Bristol Myers Squibb.

Bob Prud’Homme, PhD

Professor and Director Program in Engr. Biology

Princeton University

Saileta Prabhu, PhD

Senior Director/Head, PKPD

Genentech

Indrajit Ghosh, PhD

Senior Principal Scientist, Pharmaceutical Science and Technology

Celgene Corporation

Phillip Snyder, PhD

Associate Director, Preclinical and Pharmaceutical Sciences

Vertex Pharmaceuticals

For more information about this conference visit https://www.researchandmarkets.com/r/686hrr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900